HRP20211516T1 - Isporuka proteina na bazi bakterija oslabljene virulencije - Google Patents
Isporuka proteina na bazi bakterija oslabljene virulencije Download PDFInfo
- Publication number
- HRP20211516T1 HRP20211516T1 HRP20211516TT HRP20211516T HRP20211516T1 HR P20211516 T1 HRP20211516 T1 HR P20211516T1 HR P20211516T T HRP20211516T T HR P20211516TT HR P20211516 T HRP20211516 T HR P20211516T HR P20211516 T1 HRP20211516 T1 HR P20211516T1
- Authority
- HR
- Croatia
- Prior art keywords
- bacterial strain
- negative bacterial
- endogenous
- recombinant gram
- virulence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims 30
- 230000001018 virulence Effects 0.000 title claims 24
- 230000002238 attenuated effect Effects 0.000 title claims 17
- 102000004169 proteins and genes Human genes 0.000 title claims 15
- 241000894006 Bacteria Species 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 claims 24
- 108090000790 Enzymes Proteins 0.000 claims 10
- 102000004190 Enzymes Human genes 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims 4
- 101710096438 DNA-binding protein Proteins 0.000 claims 4
- 239000012639 bacterial effector Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000011144 upstream manufacturing Methods 0.000 claims 4
- 241000607734 Yersinia <bacteria> Species 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 3
- 239000013612 plasmid Substances 0.000 claims 3
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims 2
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims 2
- 241000896693 Disa Species 0.000 claims 2
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 claims 2
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 claims 2
- 108091005685 RIG-I-like receptors Proteins 0.000 claims 2
- 230000033228 biological regulation Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- 230000010472 type I IFN response Effects 0.000 claims 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 claims 1
- 108020004652 Aspartate-Semialdehyde Dehydrogenase Proteins 0.000 claims 1
- 108050009503 CARD domains Proteins 0.000 claims 1
- 102000002164 CARD domains Human genes 0.000 claims 1
- 101710095468 Cyclase Proteins 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 claims 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 claims 1
- 101000595918 Homo sapiens Phospholipase A and acyltransferase 4 Proteins 0.000 claims 1
- 101710090028 Inositol-3-phosphate synthase 1 Proteins 0.000 claims 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 108010006519 Molecular Chaperones Proteins 0.000 claims 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 claims 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 claims 1
- 108010013639 Peptidoglycan Proteins 0.000 claims 1
- 241001387976 Pera Species 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002759 chromosomal effect Effects 0.000 claims 1
- PDXMFTWFFKBFIN-XPWFQUROSA-N cyclic di-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 PDXMFTWFFKBFIN-XPWFQUROSA-N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000004898 n-terminal fragment Anatomy 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (14)
1. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije, odabran iz skupine koja se sastoji od rodova Yersinia, Escherichia, Salmonella, i Pseudomonas, koji obuhvaća nukleotidnu molekulu koja sadrži nukleotidnu sekvencu, koja kodira heterologni protein stopljen u okviru s 3' krajem sekvence nukleotida, koja kodira signal isporuke bakterijskog efektor proteina, pri čemu je signal isporuke bakterijskog efektor proteina bakterijski T3SS efektor protein gram – negativnog bakterijskog soja koji sadrži bakterijski T3SS efektor protein ili N-terminalni fragment istog, koji obuhvaća mjesto vezivanja pratnje, pri čemu je sekvenca nukleotida koja kodira signal isporuke bakterijskog efektor proteina operativno povezana s promotorom, i pri čemu je heterologni protein protein uključen u indukciju ili regulaciju tip I IFN odgovora odabranog iz skupine koja se sastoji od RIG-I-slične receptor (RLR) obitelji, drugih proteina koji sadrže CARD domenu i uključeni su u antiviralnu signalizaciju i tip I IFN indukciju, i ciklični dinukleotid koji generira enzime poput ciklične-di-AMP, ciklične-di-GMP i ciklične-di-GAMP ciklaze odabrane iz skupine koja se sastoji od WspR, DncV, DisA i DisA-sličnoga, CdaA, CdaS i cGAS, dovodeći do stimulacije STING-a.
2. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema patentnom zahtjevu 1, pri čemu je protein uključen u indukciju ili regulaciju tip I IFN odgovora odabran iz skupine koja se sastoji od RIG1, MDA5, MAVS/IPS-1, WspR, DncV, DisA i DisA-sličnog, CdaA, i cGAS ili njihovog fragmenta.
3. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema bilo kojem od patentnih zahtjeva 1 - 2, pri čemu rekombinantni Gram – negativni bakterijski soj oslabljene virulencije dalje obuhvaća brisanje kromosomskog gena, koji kodira endogeni protein ključan za rast i endogeni virulentni plazmid, koji obuhvaća nukleotidnu sekvencu, koja sadrži gen koji kodira navedeni endogeni protein ključan za rast, koji je operabilno povezan s promotorom.
4. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema patentnom zahtjevu 3, pri čemu je rekombinantni gram – negativni bakterijski soj oslabljene virulencije deficitan u proizvodnji barem jednog bakterijskog efektor proteina.
5. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema patentnom zahtjevu 3 ili 4, pri čemu je gen koji kodira endogeni protein ključan za rast odabran od gena koji kodira enzim ključan za proizvodnju aminokiselina, gena koji kodira enzim uključen u peptidoglikan biosintezu, gena koji kodira enzim uključen u LPS biosintezu, gena koji kodira enzim uključen u sintezu nukleotida i gena koji kodira faktor iniciranja prenošenja.
6. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema bilo kojem od patentnih zahtjeva 3 - 5, pri čemu je gen koji kodira endogeni enzim ključan za rast gen koji kodira enzim ključan za proizvodnju aminokiselina, pri čemu je enzim ključan za proizvodnju aminokiselina aspartat-beta-semialdehid dehidrogenaza (asd).
7. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema bilo kojem od patentnih zahtjeva 1 - 6, pri čemu je rekombinantni gram – negativni bakterijski soj oslabljenje virulencije Yersinia soj.
8. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema bilo kojem od patentnih zahtjeva 3 - 7, pri čemu je gen koji kodira endogeni enzim ključan za rast, i smješten je na endogenom virulentnom plazmidu, obuhvaća svoj endogeni promotor i svoj endogeni transkripcijski terminator.
9. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema patentnom zahtjevu 8, pri čemu su gen koji kodira endogeni enzim ključan za rast, njegov endogeni promotor i njegov endogeni transkripcijski terminator smješteni 122bp uzvodno od početka orf155 (SycO) na endogenom virulentnom plazmidu.
10. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema bilo kojem od patentnih zahtjeva 1 – 9, pri čemu rekombinantni gram – negativni bakterijski soj oslabljene virulencije dalje obuhvaća modulaciju na RNK termosenzorskom području uzvodno od gena koji kodira endogeni AraC-tip DNK vezujući protein odabran iz skupine koja se sastoji od VirF, LcrF, YbtA, Rns, MxiE, AraC, XylS, ExsA, PerA, MmsR, RhaS, TcpN, HrpX, HrpB, GadX, HilC, HilD, MarA, CafR, FapR i InvF.
11. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema patentnom zahtjevu 10, pri čemu modulacija na RNK termosenzorskom području uzvodno od gena koji kodira endogeni AraC-tip DNK vezujući protein obuhvaća brisanje koji briše RNK strukturu ukosnice ili njezine dijelove uzvodno od gena koji kodira endogeni AraC-tip DNK vezujući protein.
12. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema bilo kojem od patentnih zahtjeva 10 – 11, pri čemu je AraC-tip DNK vezujući protein VirF.
13. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema bilo kojem od patentnih zahtjeva 1 – 12, pri čemu je rekombinantni gram – negativni bakterijsi soj oslabljenje virulencije soj Yersinia enterolitica.
14. Rekombinantni gram – negativni bakterijski soj oslabljene virulencije prema bilo kojem od patentnih zahtjeva 1 – 13, za korištenje u metodi liječenja raka kod subjekta, metoda obuhvaća davanje subjektu spomenutog rekombinantnog gram – negativnog bakterijskog soja oslabljene virulencije, pri čemu se rekombinantni gram – negativni bakterijski soj oslabljenje virulencije subjektu daje u količini koja je dovoljna za liječenje subjekta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16205439 | 2016-12-20 | ||
| PCT/EP2017/083853 WO2018115140A2 (en) | 2016-12-20 | 2017-12-20 | Virulence attenuated bacteria based protein delivery |
| EP17837961.6A EP3559022B1 (en) | 2016-12-20 | 2017-12-20 | Virulence attenuated bacteria based protein delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211516T1 true HRP20211516T1 (hr) | 2021-12-24 |
Family
ID=57629346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211516TT HRP20211516T1 (hr) | 2016-12-20 | 2017-12-20 | Isporuka proteina na bazi bakterija oslabljene virulencije |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11518789B2 (hr) |
| EP (2) | EP3559022B1 (hr) |
| JP (1) | JP6976351B2 (hr) |
| KR (1) | KR102569949B1 (hr) |
| CN (2) | CN118006531A (hr) |
| AU (1) | AU2017384611B2 (hr) |
| BR (1) | BR112019012338A2 (hr) |
| CA (1) | CA3046852A1 (hr) |
| CL (1) | CL2019001698A1 (hr) |
| CO (1) | CO2019006675A2 (hr) |
| CY (1) | CY1124488T1 (hr) |
| DK (1) | DK3559022T3 (hr) |
| EA (1) | EA201991157A1 (hr) |
| ES (1) | ES2886672T3 (hr) |
| HR (1) | HRP20211516T1 (hr) |
| HU (1) | HUE055832T2 (hr) |
| IL (1) | IL267346A (hr) |
| LT (1) | LT3559022T (hr) |
| MA (1) | MA47119B1 (hr) |
| MX (1) | MX2019007264A (hr) |
| MY (1) | MY192537A (hr) |
| NZ (1) | NZ754510A (hr) |
| PE (1) | PE20191356A1 (hr) |
| PH (1) | PH12019550092A1 (hr) |
| PL (1) | PL3559022T3 (hr) |
| PT (1) | PT3559022T (hr) |
| RS (1) | RS62303B1 (hr) |
| SI (1) | SI3559022T1 (hr) |
| WO (1) | WO2018115140A2 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001431B (zh) | 2014-05-21 | 2022-11-01 | 巴塞尔大学 | 基于细菌的蛋白质递送 |
| EP3377094B1 (en) | 2015-11-19 | 2021-04-28 | Universität Basel | Virulence attenuated bacteria for treatment of malignant solid tumors |
| CA3005380A1 (en) | 2015-11-19 | 2017-05-26 | Universitat Basel | Bacteria-based protein delivery |
| EP3402498A1 (en) | 2016-01-11 | 2018-11-21 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| CN118006531A (zh) | 2016-12-20 | 2024-05-10 | 巴塞尔大学 | 基于减毒细菌的蛋白递送 |
| EP3847236A4 (en) * | 2018-09-06 | 2022-06-08 | Dana-Farber Cancer Institute, Inc. | CGAS/DNCV-LIKE NUCLEOTIDYL TRANSFERASES AND USES THEREOF |
| CN109825464B (zh) * | 2019-01-17 | 2021-06-15 | 浙江海洋大学 | 敲除t6ss-1基因簇的杀香鱼假单胞菌鱼用减毒疫苗 |
| US20220362361A1 (en) * | 2019-10-18 | 2022-11-17 | University Of Virginia Patent Foundation | Compositions and methods for producing enhanced immune responses and rapid antibody production |
| WO2022067219A1 (en) * | 2020-09-28 | 2022-03-31 | The Regents Of The University Of Michigan | Methods and compositions for intestinal inflammation |
| PE20231025A1 (es) * | 2020-10-27 | 2023-07-07 | T3 Pharmaceuticals Ag | Suministro de proteinas basado en bacterias |
| WO2022164937A1 (en) * | 2021-01-26 | 2022-08-04 | Christopher Bradley | Treatment of cancer using mrna-mediated virus vaccination antigens delivered by attenuated bacteria |
| CN112852698B (zh) * | 2021-01-30 | 2022-11-29 | 军事科学院军事医学研究院军事兽医研究所 | 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用 |
| CN117425671A (zh) * | 2021-03-25 | 2024-01-19 | T3制药股份公司 | 用于治疗癌症的药物组合 |
| KR20230160895A (ko) * | 2021-03-25 | 2023-11-24 | 티3 파마슈티컬스 아게 | 암을 치료하기 위한 약제 조합 |
| CN113480611B (zh) * | 2021-06-28 | 2022-12-02 | 武汉大学 | Rig-i的半胱天冬酶激活募集结构域抗病毒多肽、载体及其在制备抗病毒药物中的应用 |
| CN113699088B (zh) * | 2021-08-27 | 2023-09-15 | 集美大学 | 一株溶藻弧菌pstS基因稳定沉默菌株及其应用 |
| CN114181881A (zh) * | 2021-12-15 | 2022-03-15 | 浙江农林大学 | 基于氨基酸改造的新型减毒单增李斯特菌构建方法及应用 |
| WO2023164454A2 (en) * | 2022-02-22 | 2023-08-31 | Board Of Regents For The Oklahoma Agricultural And Mechanical Colleges | Compositions and methods for improved rhizobium-mediated plant transformation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965381A (en) * | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
| US6596509B1 (en) | 1998-07-10 | 2003-07-22 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type III secretion systems |
| US6291245B1 (en) * | 1998-07-15 | 2001-09-18 | Roche Diagnostics Gmbh | Host-vector system |
| WO2002026819A2 (en) | 2000-09-26 | 2002-04-04 | Roger Williams Hospital | Recombinant bcg vaccines for the prevention and treatment of cancer |
| WO2002077249A2 (en) | 2001-03-26 | 2002-10-03 | Universite Catholique De Louvain | Type iii bacterial strains for use in medicine |
| FR2862312B1 (fr) | 2003-11-13 | 2006-02-17 | Univ Grenoble 1 | Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas |
| EP1943344A2 (en) * | 2005-10-04 | 2008-07-16 | The Ludwig Institute for Cancer Research | Methods for stimulating an immune response using bacterial antigen delivery system |
| WO2008019183A2 (en) | 2006-05-18 | 2008-02-14 | The Regents Of The University Of California | Biopolymer and protein production using type iii secretion systems of gram negative bacteria |
| TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| EP2664339A3 (en) | 2008-03-17 | 2013-12-11 | Universitätsklinikum Münster | YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| AU2015227479B2 (en) * | 2008-11-21 | 2017-05-04 | Københavns Universitet (University Of Copenhagen) | Priming of an immune response |
| US9951340B2 (en) * | 2013-03-07 | 2018-04-24 | The General Hospital Corporation | Compositions and methods for bacterial delivery of polypeptides |
| EP3049525A4 (en) | 2013-09-24 | 2017-05-03 | Medicenna Therapeutics, Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| US10143743B2 (en) | 2013-11-18 | 2018-12-04 | Yale University | Non-replicating bacterial nanoparticle delivery system and methods of use |
| CN107001431B (zh) * | 2014-05-21 | 2022-11-01 | 巴塞尔大学 | 基于细菌的蛋白质递送 |
| CA3005380A1 (en) | 2015-11-19 | 2017-05-26 | Universitat Basel | Bacteria-based protein delivery |
| EP3377094B1 (en) | 2015-11-19 | 2021-04-28 | Universität Basel | Virulence attenuated bacteria for treatment of malignant solid tumors |
| CN118006531A (zh) | 2016-12-20 | 2024-05-10 | 巴塞尔大学 | 基于减毒细菌的蛋白递送 |
-
2017
- 2017-12-20 CN CN202410163804.7A patent/CN118006531A/zh active Pending
- 2017-12-20 RS RS20211101A patent/RS62303B1/sr unknown
- 2017-12-20 AU AU2017384611A patent/AU2017384611B2/en active Active
- 2017-12-20 ES ES17837961T patent/ES2886672T3/es active Active
- 2017-12-20 MX MX2019007264A patent/MX2019007264A/es unknown
- 2017-12-20 EA EA201991157A patent/EA201991157A1/ru unknown
- 2017-12-20 HR HRP20211516TT patent/HRP20211516T1/hr unknown
- 2017-12-20 NZ NZ754510A patent/NZ754510A/en unknown
- 2017-12-20 US US16/471,264 patent/US11518789B2/en active Active
- 2017-12-20 SI SI201730906T patent/SI3559022T1/sl unknown
- 2017-12-20 DK DK17837961.6T patent/DK3559022T3/da active
- 2017-12-20 MY MYPI2019003404A patent/MY192537A/en unknown
- 2017-12-20 EP EP17837961.6A patent/EP3559022B1/en active Active
- 2017-12-20 EP EP21182133.5A patent/EP3957645A1/en active Pending
- 2017-12-20 BR BR112019012338A patent/BR112019012338A2/pt unknown
- 2017-12-20 PL PL17837961T patent/PL3559022T3/pl unknown
- 2017-12-20 PE PE2019001289A patent/PE20191356A1/es unknown
- 2017-12-20 WO PCT/EP2017/083853 patent/WO2018115140A2/en unknown
- 2017-12-20 CA CA3046852A patent/CA3046852A1/en active Pending
- 2017-12-20 CN CN201780086910.8A patent/CN110325545B/zh active Active
- 2017-12-20 MA MA47119A patent/MA47119B1/fr unknown
- 2017-12-20 LT LTEPPCT/EP2017/083853T patent/LT3559022T/lt unknown
- 2017-12-20 KR KR1020197020458A patent/KR102569949B1/ko active IP Right Grant
- 2017-12-20 JP JP2019554020A patent/JP6976351B2/ja active Active
- 2017-12-20 PT PT178379616T patent/PT3559022T/pt unknown
- 2017-12-20 HU HUE17837961A patent/HUE055832T2/hu unknown
-
2019
- 2019-06-06 PH PH12019550092A patent/PH12019550092A1/en unknown
- 2019-06-13 IL IL267346A patent/IL267346A/en unknown
- 2019-06-19 CL CL2019001698A patent/CL2019001698A1/es unknown
- 2019-06-21 CO CONC2019/0006675A patent/CO2019006675A2/es unknown
-
2021
- 2021-08-31 CY CY20211100768T patent/CY1124488T1/el unknown
-
2022
- 2022-10-18 US US18/047,586 patent/US20230250138A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211516T1 (hr) | Isporuka proteina na bazi bakterija oslabljene virulencije | |
| JP5860464B2 (ja) | コードされたタンパク質の発現を増加させるための、ヒストンステムループおよびポリ（ａ）配列またはポリアデニル化シグナルを含むかまたはコードする核酸 | |
| US11104916B2 (en) | Compositions and methods for alphavirus vaccination | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| DK0472712T3 (da) | Sekvenser, der præferentielt eksprimeres i tidlig frøudvikling og dertil relaterede fremgangsmåder | |
| ATE386127T1 (de) | Verbesserung der immunantwort als anwendung in impfstoff und gentherapie | |
| NO20013701D0 (no) | HER-2/neu-fusjonsproteiner | |
| RS53988B1 (en) | IDENTIFICATION OF TUMOR RELATED ANTIGENS FOR DIAGNOSTICS AND THERAPY | |
| ATE521701T1 (de) | Verbesserte konstrukte zur expression lysosomaler polypeptide | |
| Matveeva et al. | Oncolysis by paramyxoviruses: preclinical and clinical studies | |
| DK1030690T3 (da) | Rekombinante vacciner, der omfatter immunogene svækkede bakterier med RpoS positiv fænotype | |
| JP2009529861A (ja) | 鳥インフルエンザウイルスのｈ５ヘマグルチニンを発現する組み換えニューキャッスル病ウイルス | |
| Acres et al. | Clinical development of MVA-based therapeutic cancer vaccines | |
| Bahlawane et al. | Fine-tuning of galactoglucan biosynthesis in Sinorhizobium meliloti by differential WggR (ExpG)-, PhoB-, and MucR-dependent regulation of two promoters | |
| PH12021551135A1 (en) | Rna encoding a protein | |
| EP4079750A3 (en) | Adenoviruses and methods for using adenoviruses | |
| Yu et al. | Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A | |
| Sampath et al. | Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses | |
| WO2018232353A4 (en) | Bacterial vaccine | |
| MX2018013524A (es) | Antígenos de consenso de filovirus, construcciones de ácido nucleico y vacunas realizadas a partir de estos, y métodos para utilizarlos. | |
| Lundstrom | Latest trends in cancer therapy applying viral vectors | |
| NO20025146D0 (no) | Isolering og karakterisering av CSA-operon (ETEC-CS4 PILI) og fremgangsmÕter for Õ anvende det samme | |
| MX2020007676A (es) | Antígenos t grandes y pequeños del poliomavirus de células de merkel, construcciones de ácido nucleico y vacunas fabricadas con ellos, y métodos de usar los mismos. | |
| CN106399591B (zh) | I型鸭肝炎病毒和鸭瘟病毒一步法pcr检测方法 | |
| EP3981880A1 (en) | Dna construct for diagnosing and treating cancer |